Lamictal (Lamotrigine) is a medication that was first approved by the FDA in 1994 for the treatment of partial seizures, later in 1998 for the treatment of Lennox-Gastaut syndrome, and again 2003 for the management of bipolar disorder. Specifically, Lamictal is used to prevent and/or treat: focal seizures, tonic-clonic seizures, and acute depressive episodes or …
Lamictal (lamotrigine) is an anticonvulsant medication prescribed for the prophylaxis and/or management of epilepsy and bipolar disorder. Research suggests that Lamictal modifies neurochemistry by: inhibiting voltage-gated sodium channels, blocking various calcium channels (L-type; N-type; P-type), antagonizing sigma and 5-HT3 receptors, upregulating GABA signaling, and suppressing the release of glutamate and aspartate. Through the aforementioned mechanisms …
Lithium is a naturally occurring element that’s commonly prescribed in the format of “lithium carbonate” for the prophylaxis and/or management of bipolar disorder. Additionally, lithium is sometimes prescribed as an adjunct to treat refractory cases of major depressive disorder and schizophrenia. Throughout treatment, lithium is understood to modulate numerous aspects of a user’s neurophysiology to …
Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adjunct) treatment for refractory major depressive disorder. Throughout the central nervous system, the medication exerts neurophysiologic effects across dopaminergic, serotonergic, noradrenergic, and histaminergic targets. Receptor sites most targeted …
Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predominantly as a: D3 and D2 receptor partial agonist, 5-HT2B receptor antagonist, and 5-HT1A partial agonist. To a less significant extent, Vraylar interacts with H1 receptors and 5-HT2A receptors as an antagonist. …
Vraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed as an adjunct for treatment-resistant depression and off-label for anxiety disorders. Although Vraylar is marketed as an improvement over older atypical antipsychotic medications in terms of efficacy and tolerability, …
Tianeptine, also referred to under the brand names “Stablon” and “Coaxil,” is an antidepressant originally discovered and patented in the 1960s by the French Society of Medical Research. The drug is primarily utilized for the treatment of major depressive disorder in France and European countries. In some cases, tianeptine is also utilized for the management …